Clinical Research Directory
Browse clinical research sites, groups, and studies.
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
Sponsor: Shanghai Zhongshan Hospital
Summary
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis, through a prospective, multicenter, randomized controlled clinical trial, starting 48 hours after endoscopic treatment to prevent rebleeding.
Official title: Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
175
Start Date
2026-06-01
Completion Date
2027-12-31
Last Updated
2026-05-22
Healthy Volunteers
No
Interventions
Rivaroxaban
Rivaroxaban 10mg qd po for 6 months
Locations (1)
Dr. Huang xiaoquan
Shanghai, China